Nils Langeland Johansen

This inventor holds 19 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Biopharmaceuticals. Top assignees: Novo Nordisk A/s, Novo Nordisk Healthcare Ag. Active years: 1998-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nils Langeland Johansen. Retrieved from https://idiyas.com/inventor/nils-langeland-johansen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 13)

% Patents Active = 63.2

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 9

Forward Citations = 283(Granted Patents)

Location History:

K.o slashed.benhavn .o slashed., DK (1998)
Herlev, DK (1999)
K.o slashed.benhavn, DK (2000)
Coppenhagen, DK (2008)
Copenhagen, DK (1998 - 2013)
København Ø, DK (2014)
Koebenhavn O, DK (2018)
Koebenhavn Oe, DK (2014 - 2022)

Company Filing History:

Novo Nordisk Healthcare Ag

patents

Years Active: 1998-2022

Loading Chart...

Areas of Expertise:

Protein Conjugates

GLP-1 Compounds

Growth Hormones

Melanocortin Receptor Agonists

Hexapeptides

Nociceptin Analogues

Hybrid Molecules

Compounds

Transglutaminase

Peptides

In-Vivo Efficacy

Formulations

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11292825 - Protein conjugates (2022-04-05),

2. 9920106 - GLP-1 compounds (2018-03-20),

3. 9695226 - Growth hormones with prolonged in-vivo efficacy (2017-07-04),

4. 8865868 - Conjugated proteins with prolonged in vivo efficacy (2014-10-21),

5. 8841249 - Growth hormones with prolonged in-vivo efficacy (2014-09-23),

6. 8779109 - Growth hormones with prolonged in-vivo efficacy (2014-07-15),

7. 8586532 - Method for selectively modifying a protein via transglutaminase catalyzed reaction (2013-11-19),

8. 7524813 - Selectively conjugated peptides and methods of making the same (2009-04-28),

9. 7517854 - Melanocortin receptor agonists (2009-04-14),

10. 7432352 - Hybrid molecules having Factor VII/VIIa activity (2008-10-07),

11. 7411039 - GLP-2 compounds, formulations, and uses thereof (2008-08-12),

12. 6350767 - Compounds with growth hormone releasing properties (2002-02-26),

13. 6127341 - Compounds with growth hormone releasing properties (2000-10-03),

14. 6013658 - Compounds with growth hormone releasing properties (2000-01-11),

15. 6011006 - Method of treating hot flushes with hexapeptides (2000-01-04),

Title: Nils Langeland Johansen: Pioneering Innovation and Sustainability

Introduction:

Nils Langeland Johansen, a renowned inventor hailing from Koebenhavn OE, Denmark, has become a respected figure in the realm of inventing due to his unwavering dedication to innovation and sustainability. His remarkable work continues to serve as a beacon of inspiration for the next generation of inventors, urging them to strive towards creating a more sustainable future.

Latest Patents:

With an impressive portfolio of 19 patents to his name, Nils Langeland Johansen's latest inventions include groundbreaking developments in the field of protein conjugates. The innovative protein conjugates he has pioneered involve the creation of compounds with a trivalent linker moiety, enabling the efficient production of desired products. Additionally, his work on novel GLP-1 compounds and their therapeutic use showcases his commitment to advancing the landscape of healthcare and pharmaceuticals.

Career Highlights:

Having made significant contributions to the industry, Nils Langeland Johansen has lent his expertise to esteemed companies such as Novo Nordisk A/S and Novo Nordisk Healthcare AG. Through his innovative solutions and forward-thinking approach, he has played a pivotal role in driving advancements within these organizations, solidifying his reputation as a visionary inventor.

Collaborations:

Throughout his career, Nils Langeland Johansen has collaborated with esteemed colleagues such as Kjeld Madsen and Bernd Peschke. These collaborative efforts have not only fostered innovation but have also led to the development of groundbreaking inventions that have left a lasting impact on the industry.

Conclusion:

In conclusion, Nils Langeland Johansen's passion for innovation and sustainability has propelled him to the forefront of the inventing world. His relentless pursuit of creating impactful solutions and his commitment to driving positive change underscore his status as a trailblazing inventor. As his work continues to inspire future generations of inventors, Nils Langeland Johansen's legacy serves as a testament to the power of innovation in shaping a more sustainable future.

Profile summary based on public USPTO records.